MEGIN US LLC

MEGIN is a global leader in magnetoencephalography (MEG) technology for functional neuroimaging. The company develops integrated solutions for clinical neurology, neurosurgery, and research applications. MEGIN's flagship product is MEG Maps™, powered by TRIUX™ neo hardware and MEG review™ software, providing seamless acquisition, database management, and analysis capabilities for presurgical evaluation and brain mapping. MEG (magnetoencephalography) is a non-invasive, real-time functional brain imaging modality that detects the small magnetic fields generated by active brain cells. MEGIN's technology localizes brain function to within centimeters or millimeters, identifying normal and abnormal activity without applied magnetic fields, radiation, or injections. The system is unaffected by skull and scalp, complementing hemodynamic data from MRI and other modalities (fMRI, PET, SPECT, TMS). Key clinical applications include presurgical evaluation and surgical planning for epilepsy, brain tumors, and neurological disorders; intracranial EEG (iEEG) placement guidance; and research in epilepsy, traumatic brain injury, PTSD, stroke, dementias, and Parkinson's disease. MEG is used in Phase I and III pharmaceutical drug development for neural mechanism assessment. Installed systems serve leading hospitals and research institutions worldwide, including Mayo Clinic, Boston Children's Hospital, Amsterdam UMC, University of Cambridge, and Swinburne University. MEGIN maintains headquarters in Espoo, Finland, with production facilities in Helsinki, and regional offices in the UK and Japan.